Review

Epigenetic modulation with histone deacetylase inhibitors in combination with immunotherapy

Jeenah Park

Department of Medicine, Hematology/Oncology Division, University of California, San Francisco, CA 94115, USA

Search for more papers by this author

Scott Thomas

Department of Medicine, Hematology/Oncology Division, University of California, San Francisco, CA 94115, USA

Search for more papers by this author

Pamela N Munster

*Author for correspondence:

E-mail Address: pmunster@medicine.ucsf.edu

Department of Medicine, Hematology/Oncology Division, University of California, San Francisco, CA 94115, USA

Search for more papers by this author

Published Online:25 Jun 2015https://doi.org/10.2217/epi.15.16

View article

Abstract

Understanding the contribution of dysregulated gene silencing to epigenomic alterations in cancer development provides the rationale for the use of epigenetic modulators, such as histone deacetylase (HDAC) inhibitors, in cancer therapy. HDAC inhibitors have been approved as single agents for cutaneous and peripheral T-cell lymphoma and have shown promising activity in reversing therapy resistance in other tumor types. The effects of HDAC inhibitors on immune modulation have created a recent interest in their potential role in immunotherapy. This review describes the current understanding on integrating HDAC inhibitors into various immunotherapeutic approaches, such as cancer vaccines, adoptive T-cell transfer and immune checkpoint inhibitors. Furthermore, it summarizes promising treatment strategies in epigenetic immune priming from clinical trials that are currently underway.

Keywords:

Papers of special note have been highlighted as: • of interest; •• of considerable interest.

References

1 Vogelstein B, Kinzler KW. Cancer genes and the pathways they control. Nat. Med. 10(8), 789–799 (2004).Crossref, Medline, CAS, Google Scholar
2 Jones PA, Baylin SB. The epigenomics of cancer. Cell 128(4), 683–692 (2007).Crossref, Medline, CAS, Google Scholar
3 Frigola J, Song J, Stirzaker C, Hinshelwood RA, Peinado MA, Clark SJ. Epigenetic remodeling in colorectal cancer results in coordinate gene suppression across an entire chromosome band. Nat. Genet. 38(5), 540–549 (2006).Crossref, Medline, CAS, Google Scholar
4 Baylin SB, Hoppener JW, de Bustros A, Steenbergh PH, Lips CJ, Nelkin BD. DNA methylation patterns of the calcitonin gene in human lung cancers and lymphomas. Cancer Res. 46(6), 2917–2922 (1986).Medline, CAS, Google Scholar
5 Feinberg AP, Vogelstein B. Hypomethylation distinguishes genes of some human cancers from their normal counterparts. Nature 301(5895), 89–92 (1983).Crossref, Medline, CAS, Google Scholar
6 Fraga MF, Ballestar E, Villar-Garea A et al. Loss of acetylation at Lys16 and trimethylation at Lys20 of histone H4 is a common hallmark of human cancer. Nat. Genet. 37(4), 391–400 (2005).Crossref, Medline, CAS, Google Scholar
7 Bolden JE, Peart MJ, Johnstone RW. Anticancer activities of histone deacetylase inhibitors. Nat. Rev. Drug Discov. 5(9), 769–784 (2006).Crossref, Medline, CAS, Google Scholar
8 Xu WS, Parmigiani RB, Marks PA. Histone deacetylase inhibitors: molecular mechanisms of action. Oncogene 26(37), 5541–5552 (2007).Crossref, Medline, CAS, Google Scholar
9 Peart MJ, Tainton KM, Ruefli AA et al. Novel mechanisms of apoptosis induced by histone deacetylase inhibitors. Cancer Res. 63(15), 4460–4471 (2003).Medline, CAS, Google Scholar
10 Thurn KT, Thomas S, Moore A, Munster PN. Rational therapeutic combinations with histone deacetylase inhibitors for the treatment of cancer. Future Oncol. 7(2), 263–283 (2011).Link, CAS, Google Scholar
11 Zou W. Immunosuppressive networks in the tumour environment and their therapeutic relevance. Nat. Rev. Cancer 5(4), 263–274 (2005).Crossref, Medline, CAS, Google Scholar
12 Hodi FS, O'Day SJ, McDermott DF et al. Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 363(8), 711–723 (2010).Crossref, Medline, CAS, Google Scholar
13 Topalian SL, Hodi FS, Brahmer JR et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N. Engl. J. Med. 366(26), 2443–2454 (2012).Crossref, Medline, CAS, Google Scholar
14 Brahmer JR, Tykodi SS, Chow LQ et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N. Engl. J. Med. 366(26), 2455–2465 (2012).Crossref, Medline, CAS, Google Scholar
15 Nie J, Liu L, Li X, Han W. Decitabine, a new star in epigenetic therapy: the clinical application and biological mechanism in solid tumors. Cancer Lett. 354(1), 12–20 (2014).Crossref, Medline, CAS, Google Scholar
16 Baylin SB, Ohm JE. Epigenetic gene silencing in cancer – a mechanism for early oncogenic pathway addiction? Nat. Rev. Cancer 6(2), 107–116 (2006).Crossref, Medline, CAS, Google Scholar
17 Brown R, Curry E, Magnani L, Wilhelm-Benartzi CS, Borley J. Poised epigenetic states and acquired drug resistance in cancer. Nat. Rev. Cancer 14(11), 747–753 (2014).Crossref, Medline, CAS, Google Scholar
18 Yang XJ, Seto E. HATs and HDACs: from structure, function and regulation to novel strategies for therapy and prevention. Oncogene 26(37), 5310–5318 (2007).Crossref, Medline, CAS, Google Scholar
19 Dhanak D, Jackson P. Development and classes of epigenetic drugs for cancer. Biochem. Biophys. Res. Commun. 455(1–2), 58–69 (2014).Crossref, Medline, CAS, Google Scholar
20 Barneda-Zahonero B, Parra M. Histone deacetylases and cancer. Mol. Oncol. 6(6), 579–589 (2012).Crossref, Medline, CAS, Google Scholar
21 Glozak MA, Sengupta N, Zhang X, Seto E. Acetylation and deacetylation of non-histone proteins. Gene 363, 15–23 (2005).Crossref, Medline, CAS, Google Scholar
22 Luo J, Li M, Tang Y, Laszkowska M, Roeder RG, Gu W. Acetylation of p53 augments its site-specific DNA binding both in vitro and in vivo. Proc. Natl Acad. Sci. USA 101(8), 2259–2264 (2004).Crossref, Medline, CAS, Google Scholar
23 Matsuzaki H, Daitoku H, Hatta M, Aoyama H, Yoshimochi K, Fukamizu A. Acetylation of Foxo1 alters its DNA-binding ability and sensitivity to phosphorylation. Proc. Natl Acad. Sci. USA 102(32), 11278–11283 (2005).Crossref, Medline, CAS, Google Scholar
24 Tsai KL, Sun YJ, Huang CY, Yang JY, Hung MC, Hsiao CD. Crystal structure of the human FOXO3a-DBD/DNA complex suggests the effects of post-translational modification. Nucleic Acids Res. 35(20), 6984–6994 (2007).Crossref, Medline, CAS, Google Scholar
25 Maruta H, Greer K, Rosenbaum JL. The acetylation of alpha-tubulin and its relationship to the assembly and disassembly of microtubules. J. Cell Biol. 103(2), 571–579 (1986).Crossref, Medline, CAS, Google Scholar
26 Cohen HY, Lavu S, Bitterman KJ et al. Acetylation of the C terminus of Ku70 by CBP and PCAF controls Bax-mediated apoptosis. Mol. Cell 13(5), 627–638 (2004).Crossref, Medline, CAS, Google Scholar
27 Thiagalingam S, Cheng KH, Lee HJ, Mineva N, Thiagalingam A, Ponte JF. Histone deacetylases: unique players in shaping the epigenetic histone code. Ann. N. Y. Acad. Sci. 983, 84–100 (2003).Crossref, Medline, CAS, Google Scholar
28 Choudhary C, Kumar C, Gnad F et al. Lysine acetylation targets protein complexes and co-regulates major cellular functions. Science 325(5942), 834–840 (2009).Crossref, Medline, CAS, Google Scholar
29 Sadoul K, Boyault C, Pabion M, Khochbin S. Regulation of protein turnover by acetyltransferases and deacetylases. Biochimie 90(2), 306–312 (2008).Crossref, Medline, CAS, Google Scholar
30 Yang H, Salz T, Zajac-Kaye M, Liao D, Huang S, Qiu Y. Overexpression of histone deacetylases in cancer cells is controlled by interplay of transcription factors and epigenetic modulators. FASEB 28(10), 4265–4279 (2014).Crossref, Medline, CAS, Google Scholar
31 Muller BM, Jana L, Kasajima A et al. Differential expression of histone deacetylases HDAC1, 2 and 3 in human breast cancer–overexpression of HDAC2 and HDAC3 is associated with clinicopathological indicators of disease progression. BMC Cancer 13, 215 (2013).Crossref, Medline, Google Scholar
32 Weichert W, Roske A, Gekeler V et al. Histone deacetylases 1, 2 and 3 are highly expressed in prostate cancer and HDAC2 expression is associated with shorter PSA relapse time after radical prostatectomy. Br. J. Cancer 98(3), 604–610 (2008).Crossref, Medline, CAS, Google Scholar
33 Wada T, Kikuchi J, Nishimura N, Shimizu R, Kitamura T, Furukawa Y. Expression levels of histone deacetylases determine the cell fate of hematopoietic progenitors. J. Biol. Chem. 284(44), 30673–30683 (2009).Crossref, Medline, CAS, Google Scholar
34 Krusche CA, Wulfing P, Kersting C et al. Histone deacetylase-1 and -3 protein expression in human breast cancer: a tissue microarray analysis. Breast Cancer Res. Treat. 90(1), 15–23 (2005).Crossref, Medline, CAS, Google Scholar
35 Marchion DC, Bicaku E, Turner JG, Schmitt ML, Morelli DR, Munster PN. HDAC2 regulates chromatin plasticity and enhances DNA vulnerability. Mol. Cancer Ther. 8(4), 794–801 (2009).Crossref, Medline, CAS, Google Scholar
36 Inoue S, Mai A, Dyer MJ, Cohen GM. Inhibition of histone deacetylase class I but not class II is critical for the sensitization of leukemic cells to tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis. Cancer Res. 66(13), 6785–6792 (2006).Crossref, Medline, CAS, Google Scholar
37 Welsbie DS, Xu J, Chen Y et al. Histone deacetylases are required for androgen receptor function in hormone-sensitive and castrate-resistant prostate cancer. Cancer Res. 69(3), 958–966 (2009).Crossref, Medline, CAS, Google Scholar
38 Yokokawa J, Cereda V, Remondo C et al. Enhanced functionality of CD4⁺CD25(^high)FoxP3⁺ regulatory T cells in the peripheral blood of patients with prostate cancer. Clin. Cancer Res. 14(4), 1032–1040 (2008).Crossref, Medline, CAS, Google Scholar
39 Nishikawa H, Sakaguchi S. Regulatory T cells in cancer immunotherapy. Curr. Opin. Immunol. 27, 1–7 (2014).Crossref, Medline, CAS, Google Scholar
40 Bridle BW, Chen L, Lemay CG et al. HDAC inhibition suppresses primary immune responses, enhances secondary immune responses, and abrogates autoimmunity during tumor immunotherapy. Mol. Ther. 21(4), 887–894 (2013).•• Authors report depletion of Treg and B cells and an increase in cytotoxic T cells when oncolytic viral vaccine is co-administered with entinostatCrossref, Medline, CAS, Google Scholar
41 Shen L, Ciesielski M, Ramakrishnan S et al. Class I histone deacetylase inhibitor entinostat suppresses regulatory T cells and enhances immunotherapies in renal and prostate cancer models. PLoS ONE 7(1), e30815 (2012).Crossref, Medline, CAS, Google Scholar
42 Tao R, de Zoeten EF, Ozkaynak E et al. Deacetylase inhibition promotes the generation and function of regulatory T cells. Nat. Med. 13(11), 1299–1307 (2007).Crossref, Medline, CAS, Google Scholar
43 Akimova T, Ge G, Golovina T et al. Histone/protein deacetylase inhibitors increase suppressive functions of human FOXP3+ Tregs. Clin. Immunol. 136(3), 348–363 (2010).Crossref, Medline, CAS, Google Scholar
44 Beier UH, Wang L, Han R, Akimova T, Liu Y, Hancock WW. Histone deacetylases 6 and 9 and sirtuin-1 control Foxp3+ regulatory T cell function through shared and isoform-specific mechanisms. Sci. Signal. 5(229), ra45 (2012).Crossref, Medline, Google Scholar
45 Zhang H, Xiao Y, Zhu Z, Li B, Greene MI. Immune regulation by histone deacetylases: a focus on the alteration of FOXP3 activity. Immunol. Cell Biol. 90(1), 95–100 (2012).Crossref, Medline, Google Scholar
46 Kim HJ, Bae SC. Histone deacetylase inhibitors: molecular mechanisms of action and clinical trials as anti-cancer drugs. Am. J. Trans. Res. 3(2), 166–179 (2011).Medline, CAS, Google Scholar
47 Shi P, Scott MA, Ghosh B et al. Synapse microarray identification of small molecules that enhance synaptogenesis. Nat. Commun. 2, 510 (2011).Crossref, Medline, Google Scholar
48 Siow RC, H JF. Redox regulation of microRNAs in health and disease. Free Radic. Biol. Med. 64, 1–3 (2013).Crossref, Medline, CAS, Google Scholar
49 West AC, Johnstone RW. New and emerging HDAC inhibitors for cancer treatment. J. Clin. Invest. 124(1), 30–39 (2014).Crossref, Medline, CAS, Google Scholar
50 Shabason JE, Tofilon PJ, Camphausen K. HDAC inhibitors in cancer care. Oncology (Williston Park) 24(2), 180–185 (2010).Medline, Google Scholar
51 Minucci S, Pelicci PG. Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat. Rev. Cancer 6(1), 38–51 (2006).Crossref, Medline, CAS, Google Scholar
52 Glaser KB, Staver MJ, Waring JF, Stender J, Ulrich RG, Davidsen SK. Gene expression profiling of multiple histone deacetylase (HDAC) inhibitors: defining a common gene set produced by HDAC inhibition in T24 and MDA carcinoma cell lines. Mol. Cancer Ther. 2(2), 151–163 (2003).Medline, CAS, Google Scholar
53 LaBonte MJ, Wilson PM, Fazzone W, Groshen S, Lenz HJ, Ladner RD. DNA microarray profiling of genes differentially regulated by the histone deacetylase inhibitors vorinostat and LBH589 in colon cancer cell lines. BMC Med. Genomics 2, 67 (2009).Crossref, Medline, Google Scholar
54 Halsall J, Gupta V, O'Neill LP, Turner BM, Nightingale KP. Genes are often sheltered from the global histone hyperacetylation induced by HDAC inhibitors. PLoS ONE 7(3), e33453 (2012).Crossref, Medline, CAS, Google Scholar
55 Siegel D, Hussein M, Belani C et al. Vorinostat in solid and hematologic malignancies. J. Hematol. Oncol. 2, 31 (2009).Crossref, Medline, Google Scholar
56 Duvic M, Talpur R, Ni X et al. Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL). Blood 109(1), 31–39 (2007).Crossref, Medline, CAS, Google Scholar
57 Modesitt SC, Sill M, Hoffman JS, Bender DP. A phase II study of vorinostat in the treatment of persistent or recurrent epithelial ovarian or primary peritoneal carcinoma: a Gynecologic Oncology Group study. Gynecol. Oncol. 109(2), 182–186 (2008).Crossref, Medline, CAS, Google Scholar
58 Luu TH, Morgan RJ, Leong L et al. A phase II trial of vorinostat (suberoylanilide hydroxamic acid) in metastatic breast cancer: a California Cancer Consortium study. Clin. Cancer Res. 14(21), 7138–7142 (2008).Crossref, Medline, CAS, Google Scholar
59 Traynor AM, Dubey S, Eickhoff JC et al. Vorinostat (NSC# 701852) in patients with relapsed non-small cell lung cancer: a Wisconsin Oncology Network phase II study. J. Thorac. Oncol. 4(4), 522–526 (2009).Crossref, Medline, Google Scholar
60 Ribas A, Wolchok JD. Combining cancer immunotherapy and targeted therapy. Curr. Opin. Immunol. 25(2), 291–296 (2013).Crossref, Medline, CAS, Google Scholar
61 Lizee G, Overwijk WW, Radvanyi L, Gao J, Sharma P, Hwu P. Harnessing the power of the immune system to target cancer. Annu. Rev. Med. 64, 71–90 (2013).Crossref, Medline, CAS, Google Scholar
62 Kantoff PW, Higano CS, Shore ND et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N. Engl. J. Med. 363(5), 411–422 (2010).Crossref, Medline, CAS, Google Scholar
63 Buonerba C, Ferro M, Di Lorenzo G. Sipuleucel-T for prostate cancer: the immunotherapy era has commenced. Expert Rev. Anticancer Ther. 11(1), 25–28 (2011).Crossref, Medline, CAS, Google Scholar
64 Breitbach CJ, Arulanandam R, De Silva N et al. Oncolytic vaccinia virus disrupts tumor-associated vasculature in humans. Cancer Res. 73(4), 1265–1275 (2013).Crossref, Medline, CAS, Google Scholar
65 Russell SJ, Peng KW, Bell JC. Oncolytic virotherapy. Nat. Biotechnol. 30(7), 658–670 (2012).Crossref, Medline, CAS, Google Scholar
66 Rosenberg SA, Yang JC, Restifo NP. Cancer immunotherapy: moving beyond current vaccines. Nat. Med. 10(9), 909–915 (2004).Crossref, Medline, CAS, Google Scholar
67 Klebanoff CA, Acquavella N, Yu Z, Restifo NP. Therapeutic cancer vaccines: are we there yet? Immunol. Rev. 239(1), 27–44 (2011).Crossref, Medline, CAS, Google Scholar
68 Lai MD, Chen CS, Yang CR et al. An HDAC inhibitor enhances the antitumor activity of a CMV promoter-driven DNA vaccine. Cancer Gene Ther. 17(3), 203–211 (2010).Crossref, Medline, CAS, Google Scholar
69 Lee SY, Huang Z, Kang TH et al. Histone deacetylase inhibitor AR-42 enhances E7-specific CD8(⁺) T cell-mediated antitumor immunity induced by therapeutic HPV DNA vaccination. J. Mol. Med. 91(10), 1221–1231 (2013).Crossref, Medline, CAS, Google Scholar
70 Bartlett DL, Liu Z, Sathaiah M et al. Oncolytic viruses as therapeutic cancer vaccines. Mol. Cancer. 12(1), 103 (2013).Crossref, Medline, Google Scholar
71 Ikeda K, Ichikawa T, Wakimoto H et al. Oncolytic virus therapy of multiple tumors in the brain requires suppression of innate and elicited antiviral responses. Nat. Med. 5(8), 881–887 (1999).Crossref, Medline, CAS, Google Scholar
72 Chang HM, Paulson M, Holko M et al. Induction of interferon-stimulated gene expression and antiviral responses require protein deacetylase activity. Proc. Natl Acad. Sci. USA 101(26), 9578–9583 (2004).Crossref, Medline, CAS, Google Scholar
73 Nusinzon I, Horvath CM. Interferon-stimulated transcription and innate antiviral immunity require deacetylase activity and histone deacetylase 1. Proc. Natl Acad. Sci. USA 100(25), 14742–14747 (2003).Crossref, Medline, CAS, Google Scholar
74 Nguyen TL, Abdelbary H, Arguello M et al. Chemical targeting of the innate antiviral response by histone deacetylase inhibitors renders refractory cancers sensitive to viral oncolysis. Proc. Natl Acad. Sci. USA 105(39), 14981–14986 (2008).• Authors demonstrate that HDAC inhibitors can be utilized to regulate cellular innate antiviral response and allow growth of therapeutic viruses within tumors.Crossref, Medline, CAS, Google Scholar
75 Otsuki A, Patel A, Kasai K et al. Histone deacetylase inhibitors augment antitumor efficacy of herpes-based oncolytic viruses. Mol. Ther. 16(9), 1546–1555 (2008).Crossref, Medline, CAS, Google Scholar
76 Rosenberg SA, Yang JC, Sherry RM et al. Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy. Clin. Cancer Res. 17(13), 4550–4557 (2011).Crossref, Medline, CAS, Google Scholar
77 Bolden JE, Shi W, Jankowski K et al. HDAC inhibitors induce tumor-cell-selective pro-apoptotic transcriptional responses. Cell Death Dis. 4, e519 (2013).Crossref, Medline, CAS, Google Scholar
78 Murakami T, Sato A, Chun NA et al. Transcriptional modulation using HDACi depsipeptide promotes immune cell-mediated tumor destruction of murine B16 melanoma. J. Invest. Dermatol. 128(6), 1506–1516 (2008).• Authors show that HDAC inhibitor depsipeptide (FK228) enhances gp100 antigen expression and promote tumor-specific T-cell-mediated killing of melanoma cells.Crossref, Medline, CAS, Google Scholar
79 Lisiero DN, Soto H, Everson RG, Liau LM, Prins RM. The histone deacetylase inhibitor, LBH589, promotes the systemic cytokine and effector responses of adoptively transferred CD8⁺ T cells. J. Immunother. Cancer 2, 8 (2014).Crossref, Medline, Google Scholar
80 Yao X, Ahmadzadeh M, Lu YC et al. Levels of peripheral CD4(⁺)FoxP3(⁺) regulatory T cells are negatively associated with clinical response to adoptive immunotherapy of human cancer. Blood 119(24), 5688–5696 (2012).Crossref, Medline, CAS, Google Scholar
81 Song DG, Ye Q, Santoro S, Fang C, Best A, Powell DJ Jr. Chimeric NKG2D CAR-expressing T cell-mediated attack of human ovarian cancer is enhanced by histone deacetylase inhibition. Hum. Gene Ther. 24(3), 295–305 (2013).Crossref, Medline, CAS, Google Scholar
82 Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat. Rev. Cancer 12(4), 252–264 (2012).Crossref, Medline, CAS, Google Scholar
83 Dong H, Strome SE, Salomao DR et al. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat. Med. 8(8), 793–800 (2002).Crossref, Medline, CAS, Google Scholar
84 Kim K, Skora AD, Li Z et al. Eradication of metastatic mouse cancers resistant to immune checkpoint blockade by suppression of myeloid-derived cells. Proc. Natl Acad. Sci. USA 111(32), 11774–11779 (2014).•• Authors report that cotreatment with epigenetic-modulating drugs (histone deacetylase inhibitor entinostat and DNA methyltransferase inhibitor 5-azacytidine) and immune check-point inhibitors (anti-PD-1 and anti-CTLA4 antibodies) cured more than 80% of the tumor-bearing mice by eliminating myeloid-derived suppressor cellsCrossref, Medline, CAS, Google Scholar
85 Juergens RA, Wrangle J, Vendetti FP et al. Combination epigenetic therapy has efficacy in patients with refractory advanced non-small cell lung cancer. Cancer Discov. 1(7), 598–607 (2011).Crossref, Medline, CAS, Google Scholar
86 Wrangle J, Wang W, Koch A et al. Alterations of immune response of non-small cell lung cancer with azacytidine. Oncotarget 4(11), 2067–2079 (2013).Crossref, Medline, Google Scholar
87 ClinicalTrials Database: NCT02032810. https://clinicaltrials.gov/ct2/show/NCT02032810.Google Scholar
88 ClinicalTrials Database:NCT01928576. https://clinicaltrials.gov/ct2/show/NCT01928576.Google Scholar
89 ClinicalTrials Database: NCT02395627. https://clinicaltrials.gov/ct2/show/NCT02395627.Google Scholar
90 Sabatier R, Finetti P, Mamessier E et al. Prognostic and predictive value of PDL1 expression in breast cancer. Oncotarget 6(7), 5449–5464 (2014).Crossref, Google Scholar

Vol. 7, No. 4

Metrics

Downloaded 630 times

History

Published online 25 June 2015

Published in print June 2015

Information

Keywords

Financial & competing interests disclosure

The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.

No writing assistance was utilized in the production of this manuscript.

PDF download